Abstract
The active metabolite (JM118) of the oral platinum analog satraplatin (JM216) was investigated for potential synergism with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. JM118 sensitivity of 7 cancer cell lines (ovarian: 2008, A2780; colon: Lovo92, WiDr; lung: A549, SW1573; epidermoid: A431), was enhanced most pronounced when JM118 preceded erlotinib, which was associated with increased formation of DNA-platinum adducts. The combination increased G2/M phase accumulation and enhanced apoptosis. JM118 increased the phosphorylation of the cell cycle proteins CDK2 and CHK1 after 24 hr exposure. JM118/erlotinib enhanced Erk and Akt phosphorylation after 2 hr. JM118 significantly decreased the phosphorylation of PTEN, VEGFR, EPHA1, ERBB4, FGF-R, andSTAT3 by 20 (PTEN) to >90% (STAT3). Conclusion: Erlotinib enhanced the effects of JM118, even in cells with mutations in Ras. The mechanism of synergy involved a combination of effects on platinum-DNA adduct formation, cell cycle distribution and signaling.
Keywords: Akt, colon cancer, Erk, erlotinib, lung cancer, satraplatin, signaling.
Current Drug Targets
Title:Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Volume: 15 Issue: 14
Author(s): Abolfazl Avan, Auke D. Adema, Eveline K. Hoebe, Charlotte M. Huijts, Amir Avan, Gareth J. Veal, Rob Ruijtenbeek, Katja Wosikowski and Godefridus J. Peters
Affiliation:
Keywords: Akt, colon cancer, Erk, erlotinib, lung cancer, satraplatin, signaling.
Abstract: The active metabolite (JM118) of the oral platinum analog satraplatin (JM216) was investigated for potential synergism with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. JM118 sensitivity of 7 cancer cell lines (ovarian: 2008, A2780; colon: Lovo92, WiDr; lung: A549, SW1573; epidermoid: A431), was enhanced most pronounced when JM118 preceded erlotinib, which was associated with increased formation of DNA-platinum adducts. The combination increased G2/M phase accumulation and enhanced apoptosis. JM118 increased the phosphorylation of the cell cycle proteins CDK2 and CHK1 after 24 hr exposure. JM118/erlotinib enhanced Erk and Akt phosphorylation after 2 hr. JM118 significantly decreased the phosphorylation of PTEN, VEGFR, EPHA1, ERBB4, FGF-R, andSTAT3 by 20 (PTEN) to >90% (STAT3). Conclusion: Erlotinib enhanced the effects of JM118, even in cells with mutations in Ras. The mechanism of synergy involved a combination of effects on platinum-DNA adduct formation, cell cycle distribution and signaling.
Export Options
About this article
Cite this article as:
Avan Abolfazl, Adema D. Auke, Hoebe K. Eveline, Huijts M. Charlotte, Avan Amir, Veal J. Gareth, Ruijtenbeek Rob, Wosikowski Katja and Peters J. Godefridus, Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141107110321
DOI https://dx.doi.org/10.2174/1389450115666141107110321 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions
Current Pharmaceutical Design Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design Oxaliplatin-induced Hyperexcitation of Rat Sciatic Nerve Fibers: An Intra-axonal Study
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Jatropha curcas: From Biodiesel Generation to Medicinal Applications
Recent Patents on Biotechnology Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews